Sample Page

Tiadenol is a hypolipidemic agent.^[1]

References

^ Potì R, Quintavalla R, Manotti C (1977). “[Clinical experimentation with a new drug lowering blood lipids (Tiadenol)]”. Giornale di Clinica Medica (in Italian). 58 (7–8): 293–300. PMID 336442.

Lipid-lowering agents (C10)

Cholesterol absorption inhibitors, NPC1L1	Ezetimibe Hyzetimibe SCH-48461
Bile acid sequestrants/resins (LDL)	Colesevelam Colestilan Colestipol Colestyramine Colextran Soluble fiber such as psyllium and glucomannan

Statins (HMG-CoA reductase, LDL)	Atorvastatin Cerivastatin^‡ Fluvastatin Lovastatin Mevastatin Pitavastatin Pravastatin Rosuvastatin Simvastatin^#
Niacin and derivatives (HDL and LDL)	Acipimox Aluminium nicotinate Nicotinic acid Niceritrol Nicofuranose Nicotinyl alcohol
MTTP inhibitors (VLDL)	Dirlotapide Lomitapide Mitratapide
ATP citrate lyase inhibitors (LDL)	Bempedoic acid
Thyromimetics (VLDL)	Dextrothyroxine^‡ Resmetirom

PPAR agonists (LDL)

Fibrates	Aluminium clofibrate Bezafibrate Choline fenofibrate Ciprofibrate Clinofibrate Clofibrate^‡ Clofibride Etofibrate Fenofibrate Gemfibrozil Nafenopin Pemafibrate Ronifibrate Simfibrate
Others	GW501516^§

CETP inhibitors (HDL)

PCSK9 inhibitors (LDL)

ANGPTL3 inhibitors (LDL/HDL)

Evinacumab

Combinations

Other

Alipogene tiparvovec
Azacosterol
Azalanstat
Benfluorex^‡
Darapladib^§
Lapaquistat^§
Magnesium pyridoxal 5-phosphate glutamate
Meglutol
Mipomersen
Olezarsen
Omega−3-acid ethyl esters
Plozasiran
Policosanol
Probucol
Tiadenol
Triparanol^‡
Volanesorsen

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III